The Effect of Far-Infrared Therapy on the Peritoneal Membrane Transport Characteristics of Uremic Patients Undergoing Peritoneal Dialysis: An Open-Prospective Proof-of-Concept Study

October 8, 2021

Abstract

Long-term peritoneal dialysis (PD) can lead to detrimental changes in peritoneal membrane function, which may be related to the accumulation of glucose degradation products. A previous study demonstrated that 6 months of far-infrared (FIR) therapy may decrease glucose degradation products in PD dialysate. Due to limited literature on this matter, this study aims to investigate the effect of FIR therapy on the peritoneal membrane transport characteristics of PD patients. Patients were grouped according to baseline peritoneal transport status: lower transporters (low and low-average) and higher transporters (high-average and high). Both groups underwent 40 min of FIR therapy twice daily for 1 year. In lower transporters, FIR therapy increased weekly dialysate creatinine clearance (6.91 L/wk/1.73 m2; p = 0.04) and D/P creatinine (0.05; p = 0.01). In higher transporters, FIR therapy decreased D/P creatinine (−0.05; p = 0.01) and increased D/D0 glucose (0.05; p = 0.006). Fifty percent of high transporter patients shifted to high-average status after FIR therapy. FIR therapy may decrease D/P creatinine for patients in the higher transporter group and cause high transporters to shift to high-average status, which suggests the potential of FIR therapy in improving peritoneal membrane function in PD patients.

-Membranes (Basel). 2021 Aug 30;11(9):669.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
August 19, 2026
A new study published in Cells has provided further insight into the molecular responses of arterial endothelial cells following far-infrared (FIR) irradiation.  The study, conducted by researchers from Gunma Paz University, Japan, investigated the effects of FIR on human femoral artery endothelial cells (HFAECs) using an integrated multi-omics approach combining transcriptomics, proteomics, and phosphoproteomics. FIR irradiation was delivered using the WSTM TY101F far-infrared therapy unit manufactured by WS Far Infrared Medical Technology.
FIRAPY at MEDICA 2026 | Innovative Care for Dialysis Patients
August 19, 2026
Meet FIRAPY at MEDICA 2026 in Düsseldorf, November 16–19. Visit Hall 16, Booth B03-2 to explore innovative far infrared therapy for dialysis patient care.
More Posts